Skin-Targeted Polypeptides for Localized Immune Privilege
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for organ transplantation and autoimmune disorders often result in chronic rejection and severe side effects due to unwanted immune responses, with existing immunosuppressive medications being ineffective in managing these conditions.
Innovation Solution
Development of polypeptides with a skin-targeting moiety and an effector binding/modulating moiety, such as PD-1 agonists or IL-2 muteins, that provide site-specific immune privilege by binding to specific cells or proteins, reducing inflammatory responses and minimizing immune rejection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broadly active immunosuppressive medications are used to combat unwanted immune responses, then immune rejection is reduced, but serious side effects occur
Solution Approach 1:
The patent applies local quality by creating site-specific immune privilege through targeted delivery of immunosuppressive effectors to specific tissues (skin, transplant organs) rather than systemic administration. The targeting moiety directs the effector molecule to bind specifically to cells in the desired tissue, providing localized immunosuppression that reduces rejection while minimizing systemic side effects.
Solution Approach 2:
The patent segments the immunosuppressive therapy into two distinct functional components: a targeting moiety that directs localization and an effector molecule that provides immunosuppression. This segmentation allows independent optimization of targeting specificity and immunosuppressive activity, enabling precise delivery of immunosuppression only where needed.
2Reliability
If existing immunosuppressive medications are used, then immune response is suppressed, but chronic rejection occurs
Solution Approach 1:
The patent applies preliminary action by establishing immune privilege at the transplant site before rejection occurs. The targeted immunosuppressive effectors are delivered to the graft site to preemptively create an immune-privileged environment, preventing the development of chronic rejection rather than treating it after onset.
Solution Approach 2:
The patent uses a targeting moiety as an intermediary that mediates between the effector molecule and the target tissue. This intermediary ensures precise delivery of the immunosuppressive agent to the graft site, maintaining effective suppression of immune responses that would otherwise lead to chronic rejection.
3Object-affected harmful factors
If site-specific immune privilege is created using targeted polypeptides, then localized immunosuppression is achieved, but device complexity increases
Solution Approach 1:
The patent merges two separate functional elements into a single polypeptide construct: the targeting moiety and the effector molecule are combined into one molecule. This merging simplifies administration (single agent rather than combination therapy) while maintaining the complexity needed for targeted delivery and localized immunosuppression.
Data Source
AI summary
Methods and compounds for conferring skin-specific immune privilege.